Immunohematologic Findings
| . | n . | % . |
|---|---|---|
| Reactivity in screening tests | ||
| Only in GAT | 5 | 2 |
| In GIFT and GAT | 65 | 27 |
| Only in GIFT | 170 | 71 |
| Ig class distribution | ||
| GIFT IgG | 204 | 85 |
| GIFT IgG and IgM | 29 | 12 |
| GIFT IgM | 7 | 3 |
| Preferential binding to panel cells | ||
| Cells from NA1 homozygous donors | 74 | 31 |
| Cells from NA2 homozygous donors | 7 | 3 |
| No preferential binding | 159 | 66 |
| Total no. of evaluated sera | 240 | |
| Complement activation | ||
| No complement activation | 30 | 50 |
| Complement activation | 30 | 50 |
| Complement-dependent cytotoxicity | 15 | 25 |
| Total no. of evaluated sera | 60 |
| . | n . | % . |
|---|---|---|
| Reactivity in screening tests | ||
| Only in GAT | 5 | 2 |
| In GIFT and GAT | 65 | 27 |
| Only in GIFT | 170 | 71 |
| Ig class distribution | ||
| GIFT IgG | 204 | 85 |
| GIFT IgG and IgM | 29 | 12 |
| GIFT IgM | 7 | 3 |
| Preferential binding to panel cells | ||
| Cells from NA1 homozygous donors | 74 | 31 |
| Cells from NA2 homozygous donors | 7 | 3 |
| No preferential binding | 159 | 66 |
| Total no. of evaluated sera | 240 | |
| Complement activation | ||
| No complement activation | 30 | 50 |
| Complement activation | 30 | 50 |
| Complement-dependent cytotoxicity | 15 | 25 |
| Total no. of evaluated sera | 60 |